Royalty Report: Drugs, Cancer, Therapeutic – Collection: 6729

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6729

License Grant
Licensor and Licensee entered into a License Agreement relating to Nimotuzumab.  Under this License Agreement, the Licensor exclusively Sub-Licensed to the Licensee the patent rights and related know-how for Nimotuzumab for the treatment of cancer in humans, for development, use and sale in Thailand, Singapore, Indonesia, Taiwan, Myanmar, Cambodia, Laos, Brunei, Philippines, Malaysia, African Republic of the Congo, Nigeria and South Africa.
License Property
Patents and know-how arising during the term of the Agreement are owned by the generating party. For the term of the Agreement, the Parties have agreed to grant to each other, an exclusive, fully-paid and royalty-free License to any arising intellectual property, in order to research, develop, make, have made, import, use, sell or otherwise deal in any products containing Nimotuzumab. The Licensee is responsible for the development and commercialization of Nimotuzumab in the agreed upon countries, in accordance with a written research and development plan, and for all costs in connection therewith.  
The Innogene License Agreement requires Innogene to purchase 100% of its supplies of Nimotuzumab for non-clinical and clinical studies and trials and 100% of its commercial supplies of Nimotuzumab from Licensor.

Patent
Technology 80.02.113
Improved Treatment Method for Cancer
  80.02.113.20

    US
  Abandoned
  627,836
  1887-39    
  80.02.113.4
    
  US
  Issued
  08/25/98
  5,798,339
  1887-79
  80.02.113.7
    
  US
  Issued
  04/08/97
  5,618,846  
  1887-134    
  80.02.113.6
    
    
  US    
  Issued
  05/05/98    
  5,747,543    
  1887-133    
  80.02.113.8
    
    
  US    
  Issued
  01/12/99    
  5,859,065    
  1887-184    
  80.02.113.2
    
    
    
  US    
  Abandoned    
  09/200,783    
  1887-190    
  80.02.113.14
    
  80.02.171.6    
  US    
  Under
  review at Patent Office    
  08/505,269    
  1887-148
  
80.02.171.12    
  US    
  Under
  review at Patent Office    
  08/773,987    
  1887-174  
    
  80.02.171.13    
  Australia    
  Issued
  02/17/94    
  693,780    
  1887-149

    Patent
Technology 80.02.194
    Method
of Treatment of Hormone-Unresponsive Metastatic Prostate Cancer
    
  File    
  Country  
  Status  
  Ser./Pat.#  
  Attorney
  Reference  
  
    
  80.02.194.1    
  US    
  Issued
  07/11/95    
  5,432,168    
  1887-93  
  
    
  80.02.194.2    
  PCT  
  Entered
  Natl. Phase    
  CA94/00676  
  1887-119

  80.02.194.9    
  US  
  Issued
  01/26/99  
  5,863,912  
  1887-164

Field of Use
The rights granted apply to the healthcare industry relating to cancer in humans.

IPSCIO Record ID: 233450

License Grant
The Parties intend to develop in Asia a therapeutic product containing glufosfamide for the treatment of cancer.

The Japanese Licensor grants an exclusive license to Licensors Know-How to make, have made, use, offer to sell, sell and import Compound Product throughout the world.

License Property
The Compound shall mean glufosfamide.

The Compound Product shall mean any product that was developed by Licensee or a sublicensee of Licensee for marketing as a therapeutic that contains the Compound and that is for the treatment of cancer.

Field of Use
The Field shall mean all human cancer therapeutic uses.

IPSCIO Record ID: 236353

License Grant
The Parties intend to develop in Asia a therapeutic product containing glufosfamide for the treatment of cancer.

The Japanese Licensor grants an exclusive license to Licensors Know-How to make, have made, use, offer to sell, sell and import Compound Product throughout the world.

License Property
The Compound shall mean glufosfamide.

The Compound Product shall mean any product that was developed by Licensee or a sublicensee of Licensee for marketing as a therapeutic that contains the Compound and that is for the treatment of cancer.

Field of Use
The Field shall mean all human cancer therapeutic uses.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.